相关实验视频
Updated: Jan 12, 2026

06:02
Detection of Neuritic Plaques in Alzheimer's Disease Mouse Model
Published on: July 26, 2011
37.3K
鲁比亚丁通过NF-κB通路调节减轻阿尔茨海默病病理
Ying Zhang1, Jia Fan1, Shanji Nan1
1Department of Neurology, The Second Hospital of Jilin University, 130041 Changchun, Jilin, China.
Journal of integrative neuroscience
|November 7, 2025
概括
鲁比亚丁 (RB) 改善了阿尔茨海默氏症患者的记忆力和减少了粉样质斑块.
科学领域:
- 神经科学是一个神经科学.
- 药理学 药理学是指药理学的学科.
- 生物化学 生物化学
背景情况:
- 阿尔茨海默病 (AD) 构成了全球重大健康挑战.
- 开发有效的AD治疗方法受到复杂的发病因子的阻碍.
- 鲁比亚丁 (RB) 正在研究其在阿尔茨海默病中的治疗潜力.
研究的目的:
- 在阿尔茨海默氏病 (AD) 模型中评估鲁比亚丁 (RB) 的神经保护作用.
- 评估RB在改善认知功能和减少AD病理方面的有效性.
- 探索RB对神经炎症和NF-κB通路的影响.
主要方法:
- 在体内 (APP/PS1小鼠) 和体内 (N2a细胞) 使用了AD.模型.
- 使用行为测试评估认知表现 (莫里斯水迷宫等). ) 的情况.
- 分析了Aβ斑块负载,炎症性细胞因子 (IL-1β,IL-6,TNF-α,IL-4) 和NF-κB通路通过免疫组织化学和西部斑点激活.
主要成果:
- 在APP/PS1小鼠中,RB显著提高了记忆性能.
- RB减少了粉样β (Aβ) 斑块的积累,并抑制了促炎性细胞因子.
- RB抑制了NF-κB通路,并保护了N2a细胞免受Aβ毒性的影响.
结论:
- 鲁比亚丁在阿尔茨海默病中显示出显著的治疗潜力.
- RB的神经保护作用与减少神经炎症和抑制NF-κB通路有关.
- 这些发现支持RB的临床前开发,用于未来的AD治疗中的临床应用.
更多相关视频
相关概念视频
NF-κB-dependent Signaling Pathway
9.7K
The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The...
NF-κB-dependent Signaling Mechanism
The...
9.7K
Alzheimer's Disease: Treatment
782
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
782
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Neural Regulation
43.1K
Digestion begins with a cephalic phase that prepares the digestive system to receive food. When our brain processes visual or olfactory information about food, it triggers impulses in the cranial nerves innervating the salivary glands and stomach to prepare for food.
43.1K
Regulated Protein Degradation
8.7K
It is vital to regulate the activity of enzymatic as well as non-enzymatic proteins inside the cell. This can be achieved either through creating a balance between their rate of synthesis and degradation or regulating the intrinsic activity of the protein. Both these regulation mechanisms play an essential role in the normal functioning of cells.
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
Protein degradation plays two important roles in the cells. It helps to protect cells from misfolded or damaged proteins before they lead to a...
8.7K

